Resources

Our latest report demonstrates the real-world success and scalable manufacturing available in the UK’s globally competitive ecosystem.

The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.

More than 110,000 people in the UK live with a muscle-wasting condition which gradually damages the way their muscles work. Over time, it stops them from living everyday life. In some cases, lives will be cut short. Through this partnership, the BIA will leverage the network it has fostered in the UK life sciences and biotech sector to support those affected by muscle-wasting conditions.

Cath Green OBE received the Peter Dunnill Award for her exceptional leadership during COVID-19; the Future Targeted Healthcare Manufacturing Hub was awarded the Richard Wilson Impact Award and Emilia Reyes Pabon received the Bioprocessing Apprentice of the Year Award.

New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

BIA and Japan Bioindustry Association signed an MOU, agreeing to work together to connect the two countries’ life sciences and biotech ecosystems to accelerate medical innovation and the commercialisation of engineering biology.

Shaun Grady will be the new Chair of BIA, effective from January 2026. He succeeds Dr Daniel Mahony, who has served as BIA Chair since January 2022 and has played a pivotal role in steering the association.

The BioIndustry Association today publishes new data revealing that the UK’s life sciences sector attracted £1.23 billion in venture capital (VC) investment in the first half of 2025, thereby putting it on track to match or surpass 2024’s total.

Responding to the Life Sciences Sector Plan, BIA Chair Dr Daniel Mahony said the following.

BIA welcomed the focus on life sciences SMEs, engineering biology, and the measures designed to help high-growth companies scale and remain rooted in the UK.

The UK’s Minster of State for Science, Research, and Innovation, Lord Patrick Vallance, London & Partners’ CEO, Laura Citron OBE, and Steve Bates OBE, CEO of the UK Bioindustry Association (BIA), are formally launching London Life Sciences Week on the UK stand at the BIO International Convention on Tuesday, 17 June 2025.

BIA has released a new explainer highlighting why the UK is well-positioned to lead in functional genomics, thanks to its unparalleled research capacity and exceptional talent pool.

Steve Bates OBE, CEO of the UK BioIndustry Association, responded to the government's Spending Review.

As the BIA Parliament Day marks its 25th year, 50 senior figures from the UK life sciences community are gathering in Westminster to urge bold government action to deliver much-needed growth for the UK economy.  

The proposals outlined in the report are a major step towards realising BIA’s long-held goal of increasing investment from UK pension funds into UK life sciences.

BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.

We are calling on the UK government to mandate pension funds to invest in high-growth UK sectors, as new data from its latest report shows British pension schemes are still missing from the biggest biotech deals. 

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, has revealed the keynote speakers for its flagship event, Drug Discovery 2025

The BioIndustry Association (BIA) has today published a report highlighting the rapid growth of the UK’s Deep Biotech sector.